Abrdn Life Sciences Investors (HQL)
NYSE: HQL · Real-Time Price · USD
15.18
+0.21 (1.40%)
Nov 7, 2024, 4:00 PM EST - Market closed

Company Description

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.

It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.

The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index.

Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Abrdn Life Sciences Investors
Abrdn Life Sciences Investors logo
Country United States
Founded 1992
Industry Asset Management
Sector Financials
CEO Daniel Omstead

Contact Details

Address:
1900 Market Street, Suite 200
Philadelphia, Pennsylvania 19103
United States
Phone 215 405 5700

Stock Details

Ticker Symbol HQL
Exchange NYSE
Reporting Currency USD
CIK Code 0000884121
CUSIP Number 87911K100
ISIN Number US87911K1007
Employer ID 04-3147016

Key Executives

Name Position
Dr. Daniel R. Omstead M.S, Ph.D. Principal Executive Officer, President and Trustee
Peter Branner Chief Investment Officer

Latest SEC Filings

Date Type Title
Sep 3, 2024 N-PX Annual Report of proxy voting record of management investment companies
Aug 28, 2024 NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
Aug 15, 2024 40-17G Filing
Jun 10, 2024 N-CSRS Filing
Jun 3, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 29, 2024 NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
May 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 22, 2024 DEF 14A Other definitive proxy statements
Apr 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership